ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 9, 2016, Pages 2397-2404

  Maertens, Johan ^a,m   Cesaro, Simone ^b,m   Maschmeyer, Georg ^c,m   Einsele, Hermann ^d,m   Donnelly, J Peter ^e   Alanio, Alexandre ^f,g,m   Hauser, Philippe ^m   Lagrou, Katrien ^a,i,m   Melchers, Willem J G ^e   Helweg Larsen, Jannik ^j,m   Matos, Olga ^k,m   Bretagne, Stéphane ^f,m   Cordonnier, Catherine ^l,m   Agrawal, Samir ^m   Kibbler, Christopher ^m   Pagliuca, Antonio ^m   Ward, Katherine ^m   Akova, Murat ^m   Herbrecht, Raoul ^m   Mallet, Vincent ^m   Ribaud, Patricia ^m   Aljurf, Mahmoud ^m   Averbuch, Dina ^m   Engelhard, Dan ^m   Berg, Thomas ^m   Cornely, Oliver ^m   Penack, Olaf ^m   van Boemmel, Florian ^m   von Lilienfeld Toal, Marie ^m   Blennow, Ola ^m   Ljungman, Per ^m   Bruggemann, Roger ^m   Donnelly, Peter ^m   Kullberg, Bart Jan ^m   Melchers, Willem ^m   Calandra, Thierry ^m   Hirsch, Hans ^m   Marchetti, Oscar ^m   Orasch, Christina ^m   Tissot, Frederic ^m   Castagnola, Elio ^m   Girmenia, Corrado ^m   Mikulska, Malgorzata ^m   Pagano, Livio ^m   Viscoli, Claudio ^m   De La Camara, Rafael ^m   Duarte, Rafael ^m   Munoz, Patricia ^m   Drgona, Lubos ^m   Hargreaves, Ruth ⁿ   Hubacek, Petr ^m   Kouba, Michal ^m   Racil, Zdenek ^m   Klyasova, Galina ^m   Pettrikos, George ^m   Roilides, Emmanuel ^m   Skiada, Anna ^m   Rizzi Puechal, Valérie ^o   Sinko, Janos ^m   Slavin, Monica ^m   Styczynski, Jan ^m   Tweddle, Lorraine ^p   Wood, Craig ^q   more..

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Policlinico Universitario gB Rossi   (Italy)

^c KLINIKUM ERNST VON BERGMANN   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^g INSTITUT PASTEUR   (France)

^h LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

ⁱ UNIVERSITY OF LEUVEN   (Belgium)

^j Rigshospitalet   (Denmark)

^k INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^l HENRI MONDOR HOSPITAL   (France)

^m Gilead Sciences ^*  (Poland)

ⁿ Stockley Park   (United Kingdom)

^o PFIZER INC   (United States)

^p Astellas   (United Kingdom)

^q MSD   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ATOVAQUONE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DAPSONE; ECHINOCANDIN; FLUDARABINE; PENTAMIDINE; RITUXIMAB; ANTIFUNGAL AGENT;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; CANCER PATIENT; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; EXPOSURE; GRAFT RECIPIENT; GROUPS BY AGE; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION PREVENTION; INFECTION RISK; PNEUMOCYSTIS PNEUMONIA; PRACTICE GUIDELINE; RECURRENT INFECTION; REVIEW; SYSTEMATIC REVIEW; ADVERSE EFFECTS; CHEMOPROPHYLAXIS; COMPLICATION; HEMATOLOGIC NEOPLASMS; IMMUNOCOMPROMISED PATIENT; PNEUMONIA, PNEUMOCYSTIS; PROCEDURES; STEM CELL TRANSPLANTATION;

ANTIFUNGAL AGENTS; CHEMOPREVENTION; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOCOMPROMISED HOST; PNEUMONIA, PNEUMOCYSTIS; STEM CELL TRANSPLANTATION; TRANSPLANT RECIPIENTS; TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION;

EID: 84991610745     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw157     Document Type: Review

References (44)

1. Cordonnier C, Cesaro S, Maschmeyer G et al. Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother 2016; doi:10.1093/jac/dkw155
2. Manoloff ES, Francioli P, Taffe P et al. Risk for Pneumocystis carinii transmission among patients with pneumonia: a molecular epidemiology study. Emerg Infect Dis 2003; 9: 132-4.
3. Miller RF, Ambrose HE, Novelli V et al. Probable mother-to-infant transmission of Pneumocystis carinii f. sp. hominis infection. J Clin Microbiol 2002; 40: 1555-7.
4. Vargas SL, Ponce CA, Gigliotti F et al. Transmission of Pneumocystis carinii DNA from a patient with P. carinii pneumonia to immunocompetent contact health care workers. J Clin Microbiol 2000; 38: 1536-8.
5. Green H, Paul M, Vidal L et al. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 2007; 82: 1052-9.
6. Green H, Paul M, Vidal L et al. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2007; issue 3: CD005590.
7. Di Cocco P, Orlando G, Bonanni L et al. A systematic review of two different trimetoprim-sulfamethoxazole regimens used to prevent Pneumocystis jirovecii and no prophylaxis at all in transplant recipients: appraising the evidence. Transplant Proc 2009; 41: 1201-3.
8. Mahon FX, Sadoun A, Benz-Lemoine E et al. Possible prevention of Pneumocystis carinii pneumonia by pentamidine aerosol after bone marrow transplantation. Bone Marrow Transplant 1991; 8: 64-5.
9. Link H, Vohringer HF,Wingen F et al. Pentamidine aerosol for prophylaxis of Pneumocystis carinii pneumonia after BMT. Bone Marrow Transplant 1993; 11: 403-6.
10. Machado CM, Macedo MC, Medeiros RS et al. Primary Pneumocystis carinii prophylaxis with aerosolized pentamidine after bone marrow transplantation. Acta Haematol 1998; 99: 54-6.
11. Vasconcelles MJ, Bernardo MV, King C et al. Aerosolized pentamidine as Pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. Biol Blood Marrow Transplant 2000; 6: 35-43.
12. Marras TK, Sanders K, Lipton JH et al. Aerosolized pentamidine prophylaxis for Pneumocystis carinii pneumonia after allogeneic marrow transplantation. Transpl Infect Dis 2002; 4: 66-74.
13. Hughes WT. Use of dapsone in the prevention and treatment of Pneumocystis carinii pneumonia: a review. Clin Infect Dis 1998; 27: 191-204.
14. Souza JP, Boeckh M, Gooley TA et al. High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis. Clin Infect Dis 1999; 29: 1467-71.
15. Sangiolo D, Storer B, Nash R et al. Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control study. Biol Blood Marrow Transplant 2005; 11: 521-9.
16. El-Sadr WM, Murphy RL, Yurik TM et al. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. N Engl J Med 1998; 339: 1889-95.
17. Chan C, Montaner J, Lefebvre EA et al. Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. J Infect Dis 1999; 180: 369-76.
18. Rodriguez M, Sifri CD, Fishman JA. Failure of low-dose atovaquone prophylaxis against Pneumocystis jiroveci infection in transplant recipients. Clin Infect Dis 2004; 38: e76-8.
19. Colby C, McAfee S, Sackstein R et al. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 24: 897-902.
20. Finkelman M. Pneumocystis jirovecii infection: cell wall (1-3)-b-D-glucan biology and diagnostic utility. Crit Rev Microbiol 2010; 36: 271-81.
21. Cushion MT, Linke MJ, Ashbaugh A et al. Echinocandin treatment of Pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection. PLoS One 2010; 5: e8524.
22. Lobo ML, Esteves F, de Sousa B et al. Therapeutic potential of caspofungin combined with trimethoprim-sulfamethoxazole for Pneumocystis pneumonia: a pilot study in mice. PLoS One 2013; 8: e70619.
23. HughesW, Kuhn S, Chaudhary S et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1977; 297: 1419-26.
24. Hughes WT, Rivera GK, Schell MJ et al. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1987; 316: 1627-32.
25. Caselli D, Petris MG, Rondelli R et al. Single-day trimethoprim/sulfamethoxazole prophylaxis for Pneumocystis pneumonia in children with cancer. J Pediatr 2013; 164: 389-92 e1.
26. Levinsen M, Shabaneh D, Bohnstedt C et al. Pneumocystis jiroveci pneumonia prophylaxis during maintenance therapy influences methotrexate/ 6-mercaptopurine dosing but not event-free survival for childhood acute lymphoblastic leukemia. Eur J Haematol 2012; 88: 78-86.
27. Agrawal AK, Chang PP, Feusner J. Twice weekly Pneumocystis jiroveci pneumonia prophylaxis with trimethoprim-sulfamethoxazole in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2011; 33: e1-4.
28. Lindemulder S, Albano E. Successful intermittent prophylaxis with trimethoprim/ sulfamethoxazole 2 days per week for Pneumocystis carinii ( jiroveci) pneumonia in pediatric oncology patients. Pediatrics 2007; 120: e47-51.
29. Ohata Y, Ohta H, Hashii Y et al. Intermittent oral trimethoprim/sulfamethoxazole on two non-consecutive days per week is effective as Pneumocystis jiroveci pneumonia prophylaxis in pediatric patients receiving chemotherapy or hematopoietic stem cell transplantation. Pediatr Blood Cancer 2009; 52: 142-4.
30. Kim SY, Dabb AA, Glenn DJ et al. Intravenous pentamidine is effective as second line Pneumocystis pneumonia prophylaxis in pediatric oncology patients. Pediatr Blood Cancer 2008; 50: 779-83.
31. Prasad P, Nania JJ, Shankar SM. Pneumocystis pneumonia in children receiving chemotherapy. Pediatr Blood Cancer 2008; 50: 896-8.
32. Mustafa MM, Pappo A, Cash J et al. Aerosolized pentamidine for the prevention of Pneumocystis carinii pneumonia in children with cancer intolerant or allergic to trimethoprim/sulfamethoxazole. J Clin Oncol 1994; 12: 258-61.
33. O'Sullivan BP, Spaulding R. The use of aerosolized pentamidine for prophylaxis of Pneumocystis carinii pneumonia in children with leukemia. Pediatr Pulmonol 1994; 18: 228-31.
34. Weinthal J, Frost JD, Briones G et al. Successful Pneumocystis carinii pneumonia prophylaxis using aerosolized pentamidine in children with acute leukemia. J Clin Oncol 1994; 12: 136-40.
35. Cheval P, Kinzonzi P, Allaert-Cheval C. Principal clinical manifestations during the course of disease caused by the human immunodeficiency virus (HIV) in Pointe-Noire (Republic of Congo). (307 cases hospitalized during 2 years at the medical service of the Regional Hospital of the Army). Med Trop (Mars) 1993; 53: 225-39.
36. Weintrub PS, Wara DW, Duliege AM. Failure of intravenous pentamidine prophylaxis for Pneumocystis carinii pneumonia. J Pediatr 1993; 122: 163-4.
37. Madden RM, Pui CH, Hughes WT et al. Prophylaxis of Pneumocystis carinii pneumonia with atovaquone in children with leukemia. Cancer 2007; 109: 1654-8.
38. HughesW, Dorenbaum A, Yogev R et al. Phase I safety and pharmacokinetics study of micronized atovaquone in human immunodeficiency virus-infected infants and children. Pediatric AIDS Clinical Trials Group. Antimicrob Agents Chemother 1998; 42: 1315-8.
39. McIntosh K, Cooper E, Xu J et al. Toxicity and efficacy of daily vs. weekly dapsone for prevention of Pneumocystis carinii pneumonia in children infected with human immunodeficiency virus. ACTG 179 Study Team. AIDS Clinical Trials Group. Pediatr Infect Dis J 1999; 18: 432-9.
40. Esbenshade AJ, Ho RH, Shintani A et al. Dapsone-induced methemoglobinemia: a dose-related occurrence? Cancer 2011; 117: 3485-92.
41. Williams S, MacDonald P, Hoyer JD et al. Methemoglobinemia in children with acute lymphoblastic leukemia (ALL) receiving dapsone for Pneumocystis carinii pneumonia (PCP) prophylaxis: a correlation with cytochrome b5 reductase (Cb5R) enzyme levels. Pediatr Blood Cancer 2005; 44: 55-62.
42. Garcia de la Fuente I, Ansari M, Rougemont AL et al. Acute disseminated fatal toxoplasmosis after haploidentical stem cell transplantation despite atovaquone prophylaxis in a young man. Pediatr Infect Dis J 2010; 29: 1059-60.
43. Megged O, Shalit I, Yaniv I et al. Breakthrough cerebral toxoplasmosis in a patient receiving atovaquone prophylaxis after a hematopoietic stem cell transplantation. Pediatr Transplant 2008; 12: 902-5.
44. Derouin F. Anti-toxoplasmosis drugs. Curr Opin Investig Drugs 2001; 2: 1368-74.